Biofron­tera will yank shares from Nas­daq; In­tel­lia and ONK col­lab­o­rate on can­cer can­di­dates

Ger­man bio­phar­ma Biofron­tera has de­cid­ed to delist its shares from the Nas­daq and dereg­is­ter its re­port­ing oblig­a­tions with the SEC in an at­tempt to re­duce com­plex­i­ty in fi­nan­cial re­port­ing and ad­min­is­tra­tive costs.

The com­pa­ny’s or­di­nary shares will still be trad­ed in the Prime Stan­dard at the Deutsche Börse un­der the sym­bol B8F. Amer­i­can share­hold­ers can choose to ex­change their Amer­i­can De­posi­tary Shares for or­di­nary shares on the Deutsche Börse, the com­pa­ny said in a re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.